Autopsy report · NCT00475657

Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer

“Terminated due to lack of efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 6 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Conditions

Small Cell Lung Cancer

Interventions

pemetrexed; cisplatin

Participants

5

Sites

6

Countries

Spain

Trials that died the same way

• An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
  “Terminated early due to a lack of efficacy.” (88% match in meaning)
• Comparing the Efficacy of Two Oral Rehydration Solutions, With or Without the Probiotic Lactobacillus Reuteri DSM 17938 and Zinc, on the Duration and Severity of Acute Gastroenteritis in 6 - 36 Months Old Children in Out-patient Care
  “Terminated due to lack of eligible patients.” (81% match in meaning)
• Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
  “Terminated due to unacceptable toxicity” (80% match in meaning)
• QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
  “Prematurely terminated due to lack of therapeutic effect” (80% match in meaning)
• A Study of Tadalafil for Duchenne Muscular Dystrophy
  “The study is being terminated for lack of efficacy” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.